keyword
MENU ▼
Read by QxMD icon Read
search

pet dementia

keyword
https://www.readbyqxmd.com/read/29136123/amyloid-network-topology-characterizes-the-progression-of-alzheimer-s-disease-during-the-predementia-stages
#1
Joana B Pereira, Tor Olof Strandberg, Sebastian Palmqvist, Giovanni Volpe, Danielle van Westen, Eric Westman, Oskar Hansson
There is increasing evidence showing that the accumulation of the amyloid-β (Aβ) peptide into extracellular plaques is a central event in Alzheimer's disease (AD). These abnormalities can be detected as lowered levels of Aβ42 in the cerebrospinal fluid (CSF) and are followed by increased amyloid burden on positron emission tomography (PET) several years before the onset of dementia. The aim of this study was to assess amyloid network topology in nondemented individuals with early stage Aβ accumulation, defined as abnormal CSF Aβ42 levels and normal Florbetapir PET (CSF+/PET-), and more advanced Aβ accumulation, defined as both abnormal CSF Aβ42 and Florbetapir PET (CSF+/PET+)...
November 9, 2017: Cerebral Cortex
https://www.readbyqxmd.com/read/29134465/current-role-for-biomarkers-in-clinical-diagnosis-of-alzheimer-disease-and-frontotemporal-dementia
#2
REVIEW
Nasim Sheikh-Bahaei, Seyed Ahmad Sajjadi, Aimee L Pierce
Purpose of review Alzheimer's disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI. However, there are certain circumstances wherein detection of specific biomarkers of neurodegeneration or underlying AD pathology will impact the clinical diagnosis or treatment plan. We will review the currently available biomarkers for AD and frontotemporal dementia (FTD) and discuss their clinical importance...
November 14, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/29130521/a-variant-in-ppp4r3a-protects-against-alzheimer-related-metabolic-decline
#3
Leigh Christopher, Valerio Napolioni, Raiyan R Khan, Summer S Han, Michael D Greicius
OBJECTIVES: A reduction in glucose metabolism in the posterior cingulate cortex (PCC) predicts conversion to Alzheimer's disease (AD) and tracks disease progression, signifying its importance in AD. We aimed to use decline in PCC glucose metabolism as a proxy for the development and progression of AD to discover common genetic variants associated with disease vulnerability. METHODS: We performed a genome-wide association study (GWAS) of decline in PCC [(18) F] FDG PET measured in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants (n=606)...
November 11, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/29123489/plasmapheresis-responsive-rapid-onset-dementia-with-predominantly-frontal-dysfunction-in-the-context-of-hashimoto-s-encephalopathy
#4
Dominique Endres, Magnus S Vry, Petra Dykierek, Anne N Riering, Eva Lüngen, Oliver Stich, Rick Dersch, Nils Venhoff, Daniel Erny, Irina Mader, Philipp T Meyer, Ludger Tebartz van Elst
Background: Hashimoto's encephalopathy (HE) is a rare immunological neuropsychiatric disorder characterized by increased antithyroid antibodies and mixed neurological and psychiatric symptoms. HE has been previously discussed as a differential diagnosis for rapid progressive dementia. However, most of these patients suffered from additional neurological symptoms, like ataxia or seizures. Case presentation: Here, we present the case of a 59-year-old female patient suffering rapid onset dementia with salient frontal executive dysfunction...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29116145/cingulate-island-sign-temporally-changes-in-dementia-with-lewy-bodies
#5
Tomomichi Iizuka, Rui Iizuka, Masashi Kameyama
The cingulate island sign (CIS) that reflects sparing of the posterior cingulate cortex (PCC) relative to the precuneus plus cuneus on FDG-PET and brain perfusion SPECT, has been proposed as a feature of dementia with Lewy bodies (DLB). As the CIS is influenced by concomitant Alzheimer's disease (AD)-type neurofibrillary tangle (NFT) pathology, we postulated that the CIS gradually disappears as DLB progresses. To determine temporal changes in the CIS, 24 patients with mild DLB and 7 with prodromal DLB underwent (123)I-IMP-SPECT and MMSE twice at an interval of two years...
November 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29114370/taming-alzheimer-s-disease-new-perspectives-newer-horizons
#6
REVIEW
Debraj Sen, Anusree Majumder, Vijinder Arora, Neha Yadu, Ritwik Chakrabarti
Alzheimer's disease (AD) is the leading cause of dementia. However, current therapies do not prevent progression of the disease. New research into the pathogenesis of the disease has brought about a greater understanding of the "amyloid cascade" and associated receptor abnormalities, the role of genetic factors, and revealed that the disease process commences 10 to 20 years prior to the appearance of clinical signs. This greater understanding of the disease has prompted development of novel disease-modifying therapies (DMTs) which may prevent onset or delay progression of the disease...
July 6, 2017: Iranian Journal of Neurology
https://www.readbyqxmd.com/read/29107051/added-value-of-18-f-florbetaben-amyloid-pet-in-the-diagnostic-workup-of-most-complex-patients-with-dementia-in-france-a-naturalistic-study
#7
Mathieu Ceccaldi, Thérèse Jonveaux, Antoine Verger, Pierre Krolak-Salmon, Claire Houzard, Olivier Godefroy, Trevor Shields, Audrey Perrotin, Rossella Gismondi, Santiago Bullich, Aleksandar Jovalekic, Nicola Raffa, Florence Pasquier, Franck Semah, Bruno Dubois, Marie-Odile Habert, David Wallon, Mathieu Chastan, Pierre Payoux, Andrew Stephens, Eric Guedj
INTRODUCTION: Although some studies have previously addressed the clinical impact of amyloid positron emission tomography (PET), none has specifically addressed its selective and hierarchical implementation in relation to cerebrospinal fluid analysis in a naturalistic setting. METHODS: This multicenter study was performed at French tertiary memory clinics in patients presenting with most complex clinical situations (i.e., early-onset, atypical clinical profiles, suspected mixed etiological conditions, unexpected rate of progression), for whom cerebrospinal fluid analysis was indicated but either not feasible or considered as noncontributory (ClinicalTrials...
November 4, 2017: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/29105977/tau-pet-imaging-predicts-cognition-in-atypical-variants-of-alzheimer-s-disease
#8
Jeffrey S Phillips, Sandhitsu R Das, Corey T McMillan, David J Irwin, Emily E Roll, Fulvio Da Re, Ilya M Nasrallah, David A Wolk, Murray Grossman
Accumulation of paired helical filament tau contributes to neurodegeneration in Alzheimer's disease (AD). (18) F-flortaucipir is a positron emission tomography (PET) radioligand sensitive to tau in AD, but its clinical utility will depend in part on its ability to predict cognitive symptoms in diverse dementia phenotypes associated with selective, regional uptake. We examined associations between (18) F-flortaucipir and cognition in 14 mildly-impaired patients (12 with cerebrospinal fluid analytes consistent with AD pathology) who had amnestic (n = 5) and non-amnestic AD syndromes, including posterior cortical atrophy (PCA, n = 5) and logopenic-variant primary progressive aphasia (lvPPA, n = 4)...
November 6, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/29094656/the-psychological-impact-of-disclosing-amyloid-status-to-japanese-elderly-a-preliminary-study-on-asymptomatic-patients-with-subjective-cognitive-decline
#9
Taisei Wake, Hajime Tabuchi, Kei Funaki, Daisuke Ito, Bun Yamagata, Takahito Yoshizaki, Masashi Kameyama, Tadaki Nakahara, Koji Murakami, Masahiro Jinzaki, Masaru Mimura
In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32))...
November 2, 2017: International Psychogeriatrics
https://www.readbyqxmd.com/read/29093372/-development-of-spect-probes-for-in-vivo-imaging-of-%C3%AE-amyloid-and-tau-aggregates-in-the-alzheimer-s-disease-brain
#10
Hiroyuki Watanabe
 Alzheimer's disease (AD) is the most common form of irreversible dementia among elderly people. In the postmortem brains of AD patients, the deposition of senile plaques composed of β-amyloid (Aβ) peptides and neurofibrillary tangles composed of highly phosphorylated tau proteins are two neuropathological hallmarks. Therefore, the in vivo imaging of Aβ and tau aggregates with positron-emission tomography (PET) or single-photon emission computed tomography (SPECT) would promote drug development, early diagnosis, and monitoring of the disease status in AD patients...
2017: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/29091778/risk-factors-for-amyloid-positivity-in-older-people-reporting-significant-memory-concern
#11
Jie Zhang, Wenjun Zhou, Ryan M Cassidy, Hang Su, Yindan Su, Xiangyang Zhang
OBJECTIVE: The goal of this study is to identify risk factors for the presence of amyloid accumulation in the brains of patients reporting subjective cognitive decline (SCD). Identifying such risk factors will help better identify patients who ought to receive neuroimaging studies to confirm plaque presence and begin intervention, as well as enhancing the study of the pathogenesis of Alzheimer's disease. METHODS: Ninety-nine SCD participants (72.2±5.6years, 57...
October 6, 2017: Comprehensive Psychiatry
https://www.readbyqxmd.com/read/29082576/longitudinal-cortical-thinning-and-cognitive-decline-in-patients-with-early-versus-late-stage-subcortical-vascular-mci
#12
Juyoun Lee, Sang Won Seo, Jin-Ju Yang, Young Kyoung Jang, Jin San Lee, Yeo Jin Kim, Juhee Chin, Jong Min Lee, Sung Tae Kim, Kyung-Han Lee, Jae Hong Lee, Jae Seung Kim, Seonwoo Kim, Heejin Yoo, Ae Young Lee, Duk L Na, Hee Jin Kim
BACKGROUND AND PURPOSE: Biomarker changes in cognitively impaired patients with small vessel disease is largely unknown. We evaluated the rate of amyloid/lacune progression, cortical thinning, and cognitive decline in subcortical vascular mild cognitive impairment (svMCI) patients. METHODS: Seventy two svMCI patients were divided into early stage (ES-svMCI, n=39) and late stage (LS-svMCI, n=33) according to their clinical dementia rating sum of box score. Patients were annually followed-up with neuropsychological tests and brain MRI for three years, and underwent a second [(11) C] Pittsburgh compound B (PiB)-PET within a mean interval of 32...
October 30, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29076399/cerebrospinal-fluid-and-blood-biomarkers-for-neurodegenerative-dementias-an-update-of-the-consensus-of-the-task-force-on-biological-markers-in-psychiatry-of-the-world-federation-of-societies-of-biological-psychiatry
#13
Piotr Lewczuk, Peter Riederer, Sid E O'Bryant, Marcel M Verbeek, Bruno Dubois, Pieter Jelle Visser, Kurt A Jellinger, Sebastiaan Engelborghs, Alfredo Ramirez, Lucilla Parnetti, Clifford R Jack, Charlotte E Teunissen, Harald Hampel, Alberto Lleó, Frank Jessen, Lidia Glodzik, Mony J de Leon, Anne M Fagan, José Luis Molinuevo, Willemijn J Jansen, Bengt Winblad, Leslie M Shaw, Ulf Andreasson, Markus Otto, Brit Mollenhauer, Jens Wiltfang, Martin R Turner, Inga Zerr, Ron Handels, Alexander G Thompson, Gunilla Johansson, Natalia Ermann, John Q Trojanowski, Ilker Karaca, Holger Wagner, Patrick Oeckl, Linda van Waalwijk van Doorn, Maria Bjerke, Dimitrios Kapogiannis, H Bea Kuiperij, Lucia Farotti, Yi Li, Brian A Gordon, Stéphane Epelbaum, Stephanie J B Vos, Catharina J M Klijn, William E Van Nostrand, Carolina Minguillon, Matthias Schmitz, Carla Gallo, Andrea Lopez Mato, Florence Thibaut, Simone Lista, Daniel Alcolea, Henrik Zetterberg, Kaj Blennow, Johannes Kornhuber
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer's disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised...
October 27, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/29072103/posterior-cortical-atrophy-of-a-suspected-non-alzheimer-type-a-case-report
#14
Mark T Wagner, Dana M Szeles, Blakely Mulder, Mimi Sohn, Aljoeson Walker
OBJECTIVE: A case of Posterior Cortical Atrophy syndrome of a suspected non-Alzheimer disease pathology type is presented to illustrate prospective diagnosis and course. METHOD: A 54-year-old woman with vague memory complaints underwent serial neuropsychological assessment, MRI, PET, and CSF screening; data are reviewed. RESULTS: While early diagnosis was confounded by multiple factors, classic visuospatial symptoms were later demonstrated using routine neuropsychological methods...
October 26, 2017: Clinical Neuropsychologist
https://www.readbyqxmd.com/read/29071066/the-emerging-role-of-pet-imaging-in-dementia
#15
REVIEW
Leonardo Iaccarino, Arianna Sala, Silvia Paola Caminiti, Daniela Perani
A compelling need in the field of neurodegenerative diseases is the development and validation of biomarkers for early identification and differential diagnosis. The availability of positron emission tomography (PET) neuroimaging tools for the assessment of molecular biology and neuropathology has opened new venues in the diagnostic design and the conduction of new clinical trials. PET techniques, allowing the in vivo assessment of brain function and pathology changes, are increasingly showing great potential in supporting clinical diagnosis also in the early and even preclinical phases of dementia...
2017: F1000Research
https://www.readbyqxmd.com/read/29070667/alzheimer-disease-brain-atrophy-subtypes-are-associated-with-cognition-and-rate-of-decline
#16
Shannon L Risacher, Wesley H Anderson, Arnaud Charil, Peter F Castelluccio, Sergey Shcherbinin, Andrew J Saykin, Adam J Schwarz
OBJECTIVE: To test the hypothesis that cortical and hippocampal volumes, measured in vivo from volumetric MRI (vMRI) scans, could be used to identify variant subtypes of Alzheimer disease (AD) and to prospectively predict the rate of clinical decline. METHODS: Amyloid-positive participants with AD from the Alzheimer's Disease Neuroimaging Initiative (ADNI) 1 and ADNI2 with baseline MRI scans (n = 229) and 2-year clinical follow-up (n = 100) were included. AD subtypes (hippocampal sparing [HpSpMRI], limbic predominant [LPMRI], typical AD [tADMRI]) were defined according to an algorithm analogous to one recently proposed for tau neuropathology...
October 25, 2017: Neurology
https://www.readbyqxmd.com/read/29067310/design-of-the-nl-enigma-study-exploring-the-effect-of-souvenaid-on-cerebral-glucose-metabolism-in-early-alzheimer-s-disease
#17
Nienke M E Scheltens, Ingrid S Kuyper, Ronald Boellaard, Frederik Barkhof, Charlotte E Teunissen, Laus M Broersen, Marieke M Lansbergen, Wiesje M van der Flier, Bart N M van Berckel, Philip Scheltens
INTRODUCTION: Alzheimer's disease is associated with early synaptic loss. Specific nutrients are known to be rate limiting for synapse formation. Studies have shown that administering specific nutrients may improve memory function, possibly by increasing synapse formation. This Dutch study explores the Effect of a specific Nutritional Intervention on cerebral Glucose Metabolism in early Alzheimer's disease (NL-ENIGMA, Dutch Trial Register NTR4718, http://www.trialregister.nl/trialreg/admin/rctview...
November 2016: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://www.readbyqxmd.com/read/29061429/role-of-inflammatory-and-hemostatic-biomarkers-in-alzheimer-s-and-vascular-dementia-a-pilot-study-from-a-tertiary-center-in-northern-india
#18
V Y Vishnu, M Modi, V K Garg, M Mohanty, M K Goyal, V Lal, B R Mittal, S Prabhakar
INTRODUCTION: A reliable plasma biomarker in differentiating between Alzheimer's disease (AD) and Vascular dementia (VaD) is the need of the hour, in most memory clinics. Even though there is no disease modifying treatment, it is important to know the type of dementia for both symptomatic treatment and prognostication. METHODS: Neuropsychological assessment, MRI brain, FDG-PET brain and CSF biomarkers of AD (Aβ42 and total tau) were used for establishing the diagnosis of Mild Cognitive Impairment (MCI), AD or VaD...
October 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/29060753/11c-pib-pet-image-analysis-for-alzheimer-s-diagnosis-using-weighted-voting-ensembles
#19
Wenjun Wu, Janani Venugopalan, May D Wang
Alzheimer's Disease (AD) is one of the leading causes of death and dementia worldwide. Early diagnosis confers many benefits, including improved care and access to effective treatment. However, it is still a medical challenge due to the lack of an efficient and inexpensive way to assess cognitive function [1]. Although research on data from Neuroimaging and Brain Initiative and the advancement in data analytics has greatly enhanced our understanding of the underlying disease process, there is still a lack of complete knowledge regarding the indicative biomarkers of Alzheimer's Disease...
July 2017: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/29053874/tau-pathology-and-neurodegeneration-contribute-to-cognitive-impairment-in-alzheimer-s-disease
#20
Alexandre Bejanin, Daniel R Schonhaut, Renaud La Joie, Joel H Kramer, Suzanne L Baker, Natasha Sosa, Nagehan Ayakta, Averill Cantwell, Mustafa Janabi, Mariella Lauriola, James P O'Neil, Maria L Gorno-Tempini, Zachary A Miller, Howard J Rosen, Bruce L Miller, William J Jagust, Gil D Rabinovici
Neuropathological and in vivo studies have revealed a tight relationship between tau pathology and cognitive impairment across the Alzheimer's disease spectrum. However, tau pathology is also intimately associated with neurodegeneration and amyloid pathology. The aim of the present study was therefore to assess whether grey matter atrophy and amyloid pathology contribute to the relationship between tau pathology, as measured with 18F-AV-1451-PET imaging, and cognitive deficits in Alzheimer's disease. We included 40 amyloid-positive patients meeting criteria for mild cognitive impairment due to Alzheimer's disease (n = 5) or probable Alzheimer's disease dementia (n = 35)...
October 7, 2017: Brain: a Journal of Neurology
keyword
keyword
94283
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"